<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03050710</url>
  </required_header>
  <id_info>
    <org_study_id>CPH-401-201258</org_study_id>
    <nct_id>NCT03050710</nct_id>
  </id_info>
  <brief_title>Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds</brief_title>
  <acronym>VINO</acronym>
  <official_title>A Prospective, Open-label, Multicenter, Post-market Study Evaluating Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Croma-Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Croma-Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, eligible subjects with moderate to severe nasolabial folds will be treated
      with Princess® VOLUME Lidocaine and will return for follow-up assessments 2, 4, 24 and 36
      weeks after the treatment. A Touch-up treatment may be done at Week 2, if deemed appropriate
      by the investigator.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 27, 2016</start_date>
  <completion_date type="Anticipated">February 10, 2018</completion_date>
  <primary_completion_date type="Actual">July 18, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Princess® VOLUME Lidocaine for the correction of nasolabial folds</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NLF-SRS grade of nasolabial folds</measure>
    <time_frame>24 weeks</time_frame>
    <description>The average change versus baseline in the NLF-SRS grade of nasolabial folds at Week 24 as evaluated by the investigator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NLF-SRS grade of nasolabial folds</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of subjects with the NLF-SRS grade reduced by ≥1 point versus baseline at Week 24</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nasolabial Fold, Hypoplastic</condition>
  <arm_group>
    <arm_group_label>Princess® VOLUME Lidocaine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Princess® VOLUME Lidocaine</intervention_name>
    <description>Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable</description>
    <arm_group_label>Princess® VOLUME Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 years of age or older

          -  Presence of two fully visible, approximately symmetrical nasolabial folds, with each
             of the folds, scored 2-3 according to the 5-grade Nasolabial Folds Severity Rating
             Scale

          -  Healthy skin in the facial area and free of diseases that could interfere in cutaneous
             aging evaluation

          -  Willingness to abstain from any aesthetic or surgical procedures in the treatment area
             for the duration of the clinical investigation

          -  Written signed and dated informed consent

        Exclusion Criteria:

          -  Pregnancy, lactation, planned pregnancy or unwillingness to use contraception at any
             time during the study (for women of child-bearing potential only)

          -  History of allergic reaction or hypersensitivity to hyaluronic acid, lidocaine, or any
             amide-based anesthetic

          -  Presence of silicone implant or another non-absorbable substance (permanent fillers)
             in the nasolabial region

          -  Presence of infectious, inflammatory, or proliferative lesions in the nasolabial
             region

          -  Cutaneous lesions in the treatment area

          -  History or presence of any autoimmune or connective tissue disease, or current
             treatment with immune therapy

          -  Use of anticoagulant, antiplatelet or thrombolytic medication

          -  Any medical condition which, in the investigator's opinion, prohibits the inclusion in
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MÄZ WIEN Medizinisch Ästhetisches Zentrum Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordination Dr. Rudolf Bartsch und Dr. Katrin Bartsch</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2017</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

